Октанейт

Octaneit is a human coagulation factor VIII medication used to manage and prevent bleeding in patients with hemophilia A. This intravenous therapy helps maintain proper blood clotting function. Octaneit is manufactured by Octapharma (Ip) Sprl and is available in the EU.

Octaneit is used to treat and prevent bleeding episodes in patients with hemophilia A, a condition that impairs the blood's ability to clot. It works by temporarily increasing factor VIII levels in the blood, supporting normal clotting processes. This medication is often prescribed for routine prophylaxis or on-demand treatment of bleeding events.

When administered, Octaneit helps restore the natural clotting ability of the blood, reducing the risk of prolonged bleeding. Patients may experience improved mobility and reduced joint damage over time with consistent use. The effects are temporary and require regular dosing to maintain adequate factor VIII levels.

Octaneit should be stored and handled according to manufacturer guidelines to maintain its potency. Always check the expiration date before use and inspect the solution for particles or discoloration. Patients should follow their healthcare provider’s instructions for administration and report any unusual symptoms immediately.

Octaneit has no known direct drug interactions, but concurrent use with other clotting agents may increase the risk of thrombosis. Patients should inform their healthcare provider about all medications, including over-the-counter products and supplements. Alcohol and certain foods do not typically interfere with Octaneit’s effectiveness.